OBJECTIVE: This study examined whether ARDS patients in whom predefined ventilator settings fail to maintain oxygenation and CO2 removal can be safely transitioned to high-frequency oscillatory ventilation (HFOV), and whether HFOV use is efficacious. DESIGN AND SETTING: Prospective observational study in the 14-bed intensive care unit of a university hospital. PATIENTS AND PARTICIPANTS: 42 patients with ARDS (APACHE II score 28 (IQR 24-37) and ventilation time prior HFOV 3.0 days (0.7-9.1). MEASUREMENTS AND RESULTS: Gas exchange parameters and ventilator data were recorded before and during HFOV treatment (-12 h, -6 h, baseline, 10 min, 1 h, 6 h, 12 h, 24 h). Primary endpoints included: (a) PaO2/FIO2 ratio 24 h after start of HFOV treatment or the last point of measurement if HFOV ended within the first 24 h; (b) HFOV-related complications. Post hoc analysis assessed the relationship between outcome and the response to HFOV, and between outcome and time of mechanical ventilation prior to HFOV. At baseline the median PaO2/FIO2 ratio was 95 (IQR 62-129); after 24 h of HFOV the PaO2/FIO2 ratio had increased significantly to 165 (88-225); only one patient developed a unilateral pneumothorax. Of the 42 patients 18 (43%) had died by day 30. Subset analyses showed a significantly higher 30-day mortality rate in patients with at least 3 days of mechanical ventilation prior to HFOV (64%) and in patients without oxygenation improvement after 24 h on HFOV (71%). CONCLUSIONS: HFOV is an effective and safe method to ventilate ARDS patients. Failure to improve oxygenation within 24 h of HFOV is associated with high mortality.
OBJECTIVE: This study examined whether ARDSpatients in whom predefined ventilator settings fail to maintain oxygenation and CO2 removal can be safely transitioned to high-frequency oscillatory ventilation (HFOV), and whether HFOV use is efficacious. DESIGN AND SETTING: Prospective observational study in the 14-bed intensive care unit of a university hospital. PATIENTS AND PARTICIPANTS: 42 patients with ARDS (APACHE II score 28 (IQR 24-37) and ventilation time prior HFOV 3.0 days (0.7-9.1). MEASUREMENTS AND RESULTS: Gas exchange parameters and ventilator data were recorded before and during HFOV treatment (-12 h, -6 h, baseline, 10 min, 1 h, 6 h, 12 h, 24 h). Primary endpoints included: (a) PaO2/FIO2 ratio 24 h after start of HFOV treatment or the last point of measurement if HFOV ended within the first 24 h; (b) HFOV-related complications. Post hoc analysis assessed the relationship between outcome and the response to HFOV, and between outcome and time of mechanical ventilation prior to HFOV. At baseline the median PaO2/FIO2 ratio was 95 (IQR 62-129); after 24 h of HFOV the PaO2/FIO2 ratio had increased significantly to 165 (88-225); only one patient developed a unilateral pneumothorax. Of the 42 patients 18 (43%) had died by day 30. Subset analyses showed a significantly higher 30-day mortality rate in patients with at least 3 days of mechanical ventilation prior to HFOV (64%) and in patients without oxygenation improvement after 24 h on HFOV (71%). CONCLUSIONS:HFOV is an effective and safe method to ventilate ARDSpatients. Failure to improve oxygenation within 24 h of HFOV is associated with high mortality.
Authors: S Mehta; S E Lapinsky; D C Hallett; D Merker; R J Groll; A B Cooper; R J MacDonald; T E Stewart Journal: Crit Care Med Date: 2001-07 Impact factor: 7.598
Authors: V M Ranieri; P M Suter; C Tortorella; R De Tullio; J M Dayer; A Brienza; F Bruno; A S Slutsky Journal: JAMA Date: 1999-07-07 Impact factor: 56.272
Authors: Stephen Derdak; Sangeeta Mehta; Thomas E Stewart; Terry Smith; Mark Rogers; Timothy G Buchman; Brian Carlin; Stuart Lowson; John Granton Journal: Am J Respir Crit Care Med Date: 2002-09-15 Impact factor: 21.405
Authors: M Monchi; F Bellenfant; A Cariou; L M Joly; D Thebert; I Laurent; J F Dhainaut; F Brunet Journal: Am J Respir Crit Care Med Date: 1998-10 Impact factor: 21.405
Authors: Edward Abraham; Peter Andrews; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Michael Pinsky; Peter Radermacher; Marco Ranieri; Christian Richard; Robert Tasker; Benoît Vallet Journal: Intensive Care Med Date: 2004-05-15 Impact factor: 17.440
Authors: Jan Florian Heuer; Philip Sauter; Jürgen Barwing; Peter Herrmann; Thomas A Crozier; Annalen Bleckmann; Tim Beißbarth; Onnen Moerer; Michael Quintel Journal: Neurocrit Care Date: 2012-10 Impact factor: 3.210
Authors: Casper W Bollen; Gijs Th J van Well; Tony Sherry; Richard J Beale; Sanjoy Shah; George Findlay; Mehran Monchi; Jean-Daniel Chiche; Norbert Weiler; Cuno S P M Uiterwaal; Adrianus J van Vught Journal: Crit Care Date: 2005-06-21 Impact factor: 9.097